Ozempic vs. Zepbound vs. Wegovy: Which One Is Actually Right for You?

Three names, one general category, and a lot of confusion about which one you actually need. If you’ve searched any of these terms, you’ve probably landed on ten different articles giving you ten slightly different answers. Here’s the version that skips the noise.

Table of Contents

First, the basic split

Ozempic and Wegovy both use semaglutide. Ozempic was approved for type 2 diabetes; Wegovy is the same active ingredient approved specifically for weight management. Same molecule, different approval pathway, and sometimes different dosing.

Zepbound and Mounjaro both use tirzepatide, a newer medication that works on two hormone pathways instead of one. Mounjaro is approved for diabetes, Zepbound for weight loss — same relationship as the semaglutide pair above.

So really, the decision usually isn’t “which brand” — it’s “semaglutide or tirzepatide,” and then which specific product fits your insurance or budget situation.

Semaglutide vs. tirzepatide: the actual difference

Tirzepatide tends to produce somewhat greater average weight loss in clinical trials, but “on average” doesn’t mean it’s automatically the better choice for you. Semaglutide has a longer track record, and for a lot of people the side-effect profile is more predictable. Tirzepatide’s dual mechanism can mean stronger appetite suppression but also potentially more pronounced GI side effects for some people early on.

Neither is objectively “the best.” It depends on your health history and what your body responds to, and honestly, some trial and error under a clinician’s guidance.

Where cost and coverage actually change the answer

This is where a lot of the “which one should I pick” content falls apart, because it ignores the part that decides the answer for most people: what your insurance will actually cover, and what you’d pay without it.

Medicare Part D coverage for GLP-1s has shifted, and a dedicated bridge program can make a real difference for eligible members
Commercial insurance coverage varies enormously plan to plan, which is why a real benefits check matters more than guessing
Cash-pay branded options exist for people without coverage, and compounded personalized versions are often significantly less expensive when appropriate for your situation

Rather than picking a medication first and then discovering what it costs, it’s usually smarter to check what’s actually accessible to you first. Body Good’s GLP-1 comparison tool lays out the medications side by side, and their treatment options page breaks down compounded vs. branded pricing directly.

Dosing schedules aren’t identical either

Semaglutide products are typically titrated up slowly over weeks to reduce side effects, and maintenance dosing varies by product and by what you’re being treated for. Tirzepatide follows a similar step-up approach but on a different schedule. This matters because rushing the titration is one of the most common reasons people experience rough side effects early on — it’s not usually the drug itself, it’s the pace.

So which one is “right”?

Honestly, the answer isn’t something you should be picking off a blog post — including this one. It depends on:

Your health history and any existing conditions
What your insurance actually covers (this narrows the list fast)
How your body responds once you start
Whether you’re treating diabetes, weight, or both

The medications aren’t interchangeable, but they’re also not competing tiers where one is “better” across the board. A licensed clinician looking at your actual intake is going to give you a more useful answer than any comparison chart, including this one.

If you want to see how the options actually line up for your specific situation, Body Good’s coverage check walks through your insurance and health history together, so the decision isn’t made in a vacuum. There’s also a Medicare-specific option for eligible members that a lot of people don’t realize applies to them until they check.